Member Info for StockWatching

A wall of new shares coming at 2.5p and I guess a lot of these investor will be looking to cash in. 2p next stop.

Revenue of £1.58m looks very light vs the guidance given at the FY results.

This was the guidance from 2024 FY £5.3m in total

"In FY2023, the majority of the Group's focus was on growing sales of AxisBiotix-PS™ in the UK and starting to push into new European territories, beginning with Spain. As stated in the trading update in July 2024, revenues of AxisBiotix-Ps are forecasted to be £400k (2024: £248k) reflecting the increase in expansion into Europe, as well as the USA through the partnership with World Products. The Group may have had limited resources to launch a product itself, however Management has been pleased with the loyalty and the very positive testimonials it continues to receive. The team also looks forward to expanding the AxisBiotix product portfolio with the launch of an acne product, following the positive consumer study.

For the two new additions to the SBTX Group, Dermatonics revenue forecast is expected to be £2.91m (2024: £1.90m), and EBITDA at £0.7m (2024: £420k), with growth across all revenue streams in the business, as well as the uplift following the Umesh Modi partnership announced earlier in 2024.

The Group will also have revenues from Bio-Tech Solutions of £2m for the period October 2024 to June 2025. On an annualised basis, this reflects revenue of £3m for the 12 months to June 2025. EBITDA is expected to come in at £0.45m."

I guess its time to raise some new funds, now with the directors in place.

When are we supposed to get an update on the Q4 drilling?

Given the urgency to raise funds after the failed $40m funding proposal, I guess there is high risk for re-set placing. The new CEO should be incentive to do that to attach his 22.5m performance right to a really low share price.

Smells like a delay is incoming

The Supreme Court has nothing to do with the VAT issue

In the last report they had the mining kit valued at $10m so this is another 40% write down.

I guess they are selling mining kit as they need all the cash they can get to keep the lights on.

I think you interpretation of FXPO serving notice under trade agreement is wrong. They would only do this when they lack means to defend them self in Ukraine courts. Which means that the are in very difficult situation.

The cash outflow from $100m at year end to $40m now is just crazy even if the trade receivable are higher and should come down.

Serving notice under the trade agreement is only useful if UK and Swiss counterparties is stepping up against Ukraine government, realistically are they going to do that right now? I have my doubt.

The other question if they steps up will they do it soon enough before Zelensky push FXPO into not going concern through or several of the measures he is putting it.

Does anyone have any idea what the dilution at the subsidiary level will be given that FSDEA and AFC is investing $15m + $38m + $54.9m in the sub through equity and convertible bonds?

I find it a bit odd that there is no information on this point in the RNS. As its a major mover for the value of PRE stake.

No one will farm in to PRD Morocco asset. They have drilled 5 wells and there hasn't been one single successful flow test. The whole project is a failure.

TW been talking about 1m in revenue for H2 2024, OPTI was not even close to that.

Argo Provides an Update on Financing Discussions

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Argo Blockchain plc (LSE: ARB; NASDAQ: ARBK) announces that the Company is no longer in financing discussions with the counter party referenced in the press release on 3 March 2025. The Company is in discussions with other interested parties and continues to work with its advisor Stifel. We will update the market as appropriate.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States. No securities may be offered or sold in the United States or to U.S. persons (as defined in Regulation S under the United States Securities Act of 1933, as amended (the "1933 Act")) unless the securities have been registered under the 1933 Act and all applicable state securities laws, or are otherwise exempt from such registration.

This announcement contains inside information

1. No sign of commercial gas in MOU-5

2. MOU-5 is duster, Paul don't have the dignity to tell the market that

3. No sign of further testing of the Morocco well, but lets be honest its pointless to keep testing rock with no commercial gas.

4. £30m valuation is crazy for a failed Morocco project and the worst Trinidad asset you can find.

We will be at sub 3p in no time.

If its rolled out across the UK the order value based on population would be in the region of £12-14m. Which would be significant for GDR.

Commercial break through

Scottish Government announcement of investment to support national pharmacogenetic testing of CYP2C19 in Stroke patients and MT-RNR1 in newborn babies in NHS Scotland.

genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, is pleased to note an announcement by the Scottish Government of investment into phased delivery of two national scale pharmacogenetic testing programs utilising genedrive's MT-RNR1-ID and CYP2C19-ID kits in NHS Scotland. The public announcement is available at https://www.gov.scot/news/improving-health-through-innovation/.

The initial deployment of these programmes is through funding being provided to the Accelerated National Adoption ("ANIA") pathway following referral from ANIA to the Scottish Health Technologies Group ("SHTG") which carried out two technology assessments that included both the Genedrive® CYP2C19 ID Kit and the Genedrive® MT-RNR1 ID Kit. Subsequently, Scotland's First Minister John Swinney delivered a speech on NHS Renewal & Recovery on 27 January 2025 (https://www.youtube.com/live/-tWX1ESlpSs) during which he stated (38:40), "The latest innovations in genetic testing will be harnessed to enable better targeting of medications, in cases ranging from recent stroke patients to newborn infants with bacterial infections. Smarter care, better care".

As outlined in the Scottish Government announcement, approximately £800,000 will fund testing newborn babies with genedrive's MT-RNR-ID kit, in a phased national roll out over 18 months with first clinical testing beginning in October. Once fully implemented it is expected that over 3,000 babies per year will receive the MT-RNR1-ID test throughout Scotland. A total of £1.1 million will support interventional CYP2C19 testing in recent stroke patients and whilst primarily focused on laboratory based testing with substantially slower turnaround times, Genedrive's CYP2C19-ID kit will be included for assessment against laboratory testing pathways in Transient Ischaemic Attack ("TIA") clinics.

Dr Gino Miele, CEO of genedrive plc, said: "This announcement from the Scottish Government is a welcome commitment to the strategic implementation of pharmacogenetic testing into clinical pathways at national scale in NHS Scotland. Aside from enabling significantly better patient outcomes, these interventional testing paradigms offer substantial financial value to pressured healthcare systems. Against a backdrop of increasing paradigm shifts from treatment to prevention and speedier, less centralised diagnostics, and also recent UK government announcements to abolish NHS England as an organisation and loss of 9,000 jobs with accompanying savings of £500m per year, it is noteworthy that CYP2C19 interventional testing alone is estimated to offer one-third of this at approximately £160m per year of value to NHS England. We look forward to working with colleagues in ANIA, and are grateful for their integrated efforts

They are out already

Its time to move on.

Recruitment of Second Patient for HG-CT-1 Clinical Trial

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce the recruitment of the second patient for its clinical trial of HG-CT-1, its proprietary CAR-T cell therapy, for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults. This marks a significant step forward in the Company's clinical development program and underscores the progress toward delivering a potentially life-saving treatment for AML patients with limited therapeutic options.

The manufacturing of HG-CT-1 for the second patient, carried out by the Company's team of scientists and quality control professionals, is scheduled to commence shortly.

Further updates on the clinical trial will be provided in due course.

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:

"The recruitment of the second patient is indicative of the promising results of the clinical trial for HG-CT-1 thus far and represents another critical step in advancing HG-CT-1 as a potential breakthrough treatment for relapsed or refractory AML. This milestone reflects the dedication of our team and the strength of our science, bringing us closer to addressing an urgent unmet medical need."